Kaposi Sarcoma in HIV Positive Nigerian Children: A Case Series
Regina Oladokun, Bamidele Kolude, Gabriel Ogun, Biobele Brown, Kikelomo Osinusi
DOI: 10.4236/wja.2011.13010   PDF    HTML     5,566 Downloads   10,889 Views   Citations


Background: HIV associated KS is relatively rare in children and has been reported to be higher in East Africa compared to other regions. Literature on cases of histologically proven Kaposi sarcoma in children with HIV infection in West Africa is scanty. Case presentation: This communication presents three cases of KS seen among children in a paediatric HIV unit. The first case was an eleven year old HIV positive boy who had oral candidiasis that resolved with treatment and subsequently developed a painless, erythematous swelling at the middle of the dorsum of the tongue with central loss of papillae. He also had multiple discoid hyperpigmented flat lesions on the legs and soles of the feet. In addition to switching to second line antiretroviral therapy, he had chemotherapy. The lesions regressed. The second case was a double orphan who had KS involvement of the right eye, nasal cavity and lymph nodes. The tumour rapidly progressed and the child died before ART and chemotherapy could be commenced. The last case was a five year old girl with mild KS of the skin but also had other manifestations of severe HIV disease which she succumbed to. Incisional biopsies of the lesions revealed an invasive epithelial lined vascular tumour destroying the upper layers of skeletal fibres within the connective tissue stroma in keeping with KS. Human Herpes Virus type 8 (HHV8) screen was also positive for all the cases. Conclusion: A high index of suspicion must be entertained and biopsy of suspicious muco-cutaneous lesions is necessary to exclude a diagnosis of KS which is an indicator of severity and progression of HIV.

Share and Cite:

R. Oladokun, B. Kolude, G. Ogun, B. Brown and K. Osinusi, "Kaposi Sarcoma in HIV Positive Nigerian Children: A Case Series," World Journal of AIDS, Vol. 1 No. 3, 2011, pp. 63-69. doi: 10.4236/wja.2011.13010.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] K. Ranganathan and R. Hemalatha, “Oral Lesions in HIV Infections in Developing Countries: An overview,” Advances in Dental Research, Vol. 19, No. 1, 2006, pp. 63-68. doi:10.1177/154407370601900113
[2] J. L. Ziegler and E. Katongole-Mbidde, “Kaposi’s Sarcoma in Childhood: An Analysis of 100 Cases from Uganda and Relationship to HIV Infection,” International Journal of Cancer, Vol. 65, No. 2, 1996, pp. 200-203. doi:10.1002/(SICI)1097-0215(19960117)65:2<200::AID-IJC12>3.0.CO;2-H
[3] L. Feller and J. Lemmer, “HIV-Associated Kaposi’s Sarcoma: Pathogenic Mechanisms,” Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, Vol. 104, No. 4, 2007, pp. 521-529. doi:10.1016/j.tripleo.2006.08.015
[4] K. P. Manji, H. Amir and I. Z. Maduhu, “Aggressive Kaposi’s Sarcoma in a 6-Month-Old African Infant: Case Report and Review of the Literature,” Tropical Medicine & International Health, Vol. 5, No 2, 2000, pp. 85-87. doi:10.1046/j.1365-3156.2000.00523.x
[5] A. K. Agarwal, G. Zamzachin, Y.Mohen, M. Y. Singh and N. Singh, “AIDS Related Kaposi’s Sarcoma—Like Lesion,” Indian Journal of Dermatology, Vol. 62, No. 2, 1996, pp. 129-131.
[6] J. B. Epstein, R. J. Cabey and M. Glick, “Oral Malignancies in HIV Disease: Changes in Disease Presentation, Increasing Understanding of Molecular Pathogenesis and Current Management,” Oral Surgery Oral Medicine Oral Pathology Oral Radiology, and Endodontics, Vol. 100, No. 5, 2005, pp. 571-578. doi:10.1016/j.tripleo.2005.01.015
[7] P. Khongkunthlan, M.Grote, W. Isaratanan, S. Plyaworawong and P. A. Reichart, “Oral Manifestations in 45 HIV-Positive Children from Northern Thailand,” Journal of Oral Pathology & Medicine, Vol. 30, No. 9, 2001, pp. 549-552. doi:10.1034/j.1600-0714.2001.300907.x
[8] I. D. Miziara, B. C. Araújo Filho and R. Weber, “Oral Lesions in Brazilian HIV-Infected Children Undergoing HAART,” International Journal of Pediatric Otorhinolaryngology, Vol. 70, No. 6, 2006, pp. 1089-1096. doi:10.1016/j.ijporl.2005.11.010
[9] I. Lager, M. Altini, H. Coleman and H. Ali, “Oral Kaposi’s Sarcoma: A Clinicopathologic Study from South Africa,” Oral Surgery Oral Medicine Oral Pathology Oral Radiology, and Endodontics, Vol. 96, No. 6, 2003, pp. 701-710. doi:10.1016/S1079-2104(03)00370-6
[10] M. M. Taylor, B. B. Chohan, L. Lavreys, W. Hassan, M. L. Huang, L. Corey, R. Ashley Morrow, B. A. Richardson, K. Mandaliya, J. Ndinya-Achola, J. Bwayo and J. Kreiss, “Shedding of Human HerpesVvirus 8 in Oral and Genital Secretions from HIV-1 Seropositive and Seronegative Kenyan Women,” Journal of Infectious Diseases, Vol. 190, No. 3, 2004, pp. 484-488. doi:10.1086/421466
[11] B. Rohrmus, E. M. Thoma-Greber, M. Rocken and J. R. Bogner, “Outlook in Oral and Cutaneous Kaposi’s Sarcoma,” Lancet, Vol. 356, No. 9248, 2000, p. 2160. doi:10.1016/S0140-6736(00)03503-0
[12] A. E. Friedman-Kien, L J. Laubenstein, P. Rubinstein, E. Buimovici-Klein, M. Marmor, R. Stahl, I. Spigland, K. S. Kim and S. Zolla-Pazner, “Disseminated Kaposi’s Sarcoma in Homosexual Men,” Annals of internal medicine, Vol. 96, No. 6, 1982, pp. 693-700.
[13] P. C. Windle-Taylor and N. Shah, “Oropharyngeal Kaposi’s Sarcoma: Report of Two Cases and Review of the Literature,” Journal of Laryngology and Otology, Vol. 97, No. 11, 1993, pp. 1065-1071.
[14] C. Oji and F. Chukwuneke, “Clinical Evaluation of Kaposi Sarcoma in HIV/AIDS Patients with Orofacial Lesions in Enugu, Nigeria,” Journal of Oral Maxillofacial Surgery, Vol. 66, No. 7, 2008, pp. 1362-1365. doi:10.1016/j.joms.2007.08.049
[15] M. I. Adurogbangba, G. A. Aderinokun, G. N. Odaibo, O. D. Olaleye and T. O. Lawoyin, “Oro-Facial Lesions and CD4 Counts Associated with HIV/AIDS in an Adult Population in Oyo State, Nigeria,” Oral Diseases, Vol. 10, No. 6, 2004, pp. 319-326. doi:10.1111/j.1601-0825.2004.01036.x
[16] G. A. Agbelusi and A. A. Wright, “Oral Lesions as Indicators of HIV Infection among Routine Dental Patients in Lagos, Nigeria,” Oral Diseases, Vol. 11, No. 8, 2005, pp. 370-373.
[17] Federal Ministry of Health of Nigeria, “National Guidelines on Cancer Chemotherapy,” Federal Ministry of Health of Nigeria, 2008.
[18] N. Mbah, I. H. Abdulkareem and A. Panti, “AIDS-Associated Kaposi’s Sarcoma in Sokoto, Nigeria,” Nigerian Journal of Clinical Practice, Vol. 11, No. 3, 2008, pp. 181-184.
[19] D. C. Stefan, D. K. Stones, L. Wainwright and R. Newton, “Kaposi Sarcoma in South African Children,” Pediatric Blood Cancer, Vol. 56, No. 3, 2011, pp. 392-396. doi:10.1002/pbc.22903
[20] A. Mosam, J. Aboobaker and F. Shaik, “Kaposi’s Sarcoma in Sub-Saharan Africa: A Current Perspective,” Current Opinion in Infectious Diseases, Vol. 23, 2010, pp. 119-123.
[21] S. Theron, S. Andronikou, R. George, J. du Plessis, P. Goussard, M. Hayes, A. Mapukata and R. Gie, “Non-Infective Pulmonary Disease in HIV-Positive Children,” Pediatric Radiology, Vol. 39, No. 6, 2009, pp. 555-564. doi:10.1007/s00247-009-1156-2
[22] C. Okunseri, V. Badner, A. Wiznia and M. Rosemberg, “Prevalence of Oral lesions and Percent CD41+ T-Lym- Phocytes in HIV Infected Children on Antiretroviral Therapy,” AIDS Patient Care and STDS, Vol. 17, No. 1, 2003, pp. 5-11. doi:10.1089/108729103321042863
[23] A. Chan, A. Milnes, S. M. King and S. Read, “The Relationship of Oral Manifestations to Parameters of Immune Function and CDC Stage in Children Born to HIV Positive Women,” In: Pediatric AIDS and HIV Infection: Fetus to Adolescent, Williams & Wilkins, Baltimore, 1994, pp. 101-107.
[24] B. Ensoli, R. Gendelman, P. Markham, V. Fiorelli, S. Colombini, M. Raffeld, A. Cafero, H. K. Chang, J. N. Brady and R. C. Gallo, “Synergy between Basic Fibroblast Growth Factor and HIV-1 Tat Protein in Induction of Kaposi’s Sarcoma,” Nature, Vol. 371, 1994, pp. 674-680. doi:10.1038/371674a0
[25] M. W. Kline, “Oral Manifestations of Pediatric Human Immunodeficiency Virus Infection: A Review of the Literature,” Pediatrics, Vol. 97, No. 3, 1996, pp. 380-388.
[26] J. A. Sparano, X. Hu, P. H. Wiernik, C. Sarta, D. M. Reddy, L. Hanau and D. H. Henry, “Opportunistic Infection and Immunologic Function in Patients with Human Immunodeficiency Virus-Associated Non-Hodgkin’s Lymphoma Treated with Chemotherapy,” Journal of the National Cancer Institute, Vol. 89, No. 4, 1997, pp. 301-307. doi:10.1093/jnci/89.4.301
[27] A. Plettenberg, U. van Dyk, A. Stoehr, H. Albrecht, H. J. Stellbrink, J. Berger and W. Meigel, “Increased Risk for Opportunistic Infections during Chemotherapy in HIV-In- fected Patients with Kaposi’s Sarcoma,” Dermatology, Vol. 194, No. 3, 1997, pp. 234-237. doi:10.1159/000246109
[28] D. M. Murdoch, W. D. Venter, C. Feldman and A. Van Rie, “Incidence and Risk Factors for the Immune Reconstitution Inflammatory Syndrome in HIV Patients in South Africa: A Prospective Study,” AIDS, Vol. 22, No. 5, 2008, pp. 601-610. doi:10.1097/QAD.0b013e3282f4a607
[29] E. Letang, J. Almeida, E. Ayala, I. E. White, C. Carrilho, R. Bastos, T. Nhampossa, C. Menéndez, T. B. Campbell, P. L. Alonso, D. Naniche, “Predictors of Immune Reconstitution Inflammatory Syndrome-Associated with Kaposi Sarcoma in Mozambique: A Prospective Study,” Journal of Acquired Immune Deficiency Syndrome, Vol. 53, No. 5, 2010, pp. 589-597.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.